Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC

Welcome to a very special edition of OncLive^® On Air! I’m your host today, Caroline Seymour.

OncLive^® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we passed the mic to Charu Aggarwal, MD, MPH, a medical oncologist at Abramson Cancer Center and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine, who moderated a discussion on the phase 3 ADAURA trial and the use of adjuvant osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Aggarwal was joined by Lecia V. Sequist, MD, MPH, the Landry Family Professor of Medicine at Harvard Medical School, director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital, and a medical oncologist at Massachusetts General Hospital Cancer Center, and Nathan Pennell, MD, PhD, professor of medicine and member of the Developmental Therapeutics Program at Case Comprehensive Cancer Center, a medical oncologist at the Taussig Cancer Center, and director of the Lung Cancer Program at Cleveland Clinic.

In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.